Seres Therapeutics (NASDAQ:MCRB) Given Buy Rating at Chardan Capital
Seres Therapeutics (NASDAQ:MCRB – Get Free Report)‘s stock had its “buy” rating restated by equities research analysts at Chardan Capital in a research report issued on Thursday,Benzinga reports. They presently have a $1.25 price target on the biotechnology company’s stock. Chardan Capital’s price objective points to a potential upside of 75.73% from the stock’s current […]
Seres Therapeutics (NASDAQ:MCRB – Get Free Report)‘s stock had its “buy” rating restated by equities research analysts at Chardan Capital in a research report issued on Thursday,Benzinga reports. They presently have a $1.25 price target on the biotechnology company’s stock. Chardan Capital’s price objective points to a potential upside of 75.73% from the stock’s current […]
